Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Human Papillomavirus 16 Positive Hpv16 Cancers Market

DelveInsight’s ‘HPV 16+ Cancer– Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the HPV 16+ Cancer, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The HPV 16+ Cancer market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted HPV 16+ Cancer symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current HPV 16+ Cancer symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • EU5
  • Japan

 Study Period: 2018–2030

HPV 16+ Cancer Disease Understanding and Treatment Algorithm

HPV 16+ Cancer Overview

Human papillomavirus (HPV) is a double-stranded DNA virus that infects squamous cells such as skin, oral, vaginal, anal, and nasal epithelium. The basal cells in the epithelium are the targets and, once infected, act as the reservoir for the virus. Viral replication occurs mainly in the epithelial cells that have completed cell division and are progressing to desquamation. Desquamation releases the viral particles and completes the viral replication cycle. Worldwide, the major oncogenic HPV subtypes are 16 and 18, which account for most of the HPV-related cancers.


HPV infects the squamous cells that line the inner surfaces of these organs. For this reason, most HPV-related cancers are a type of cancer called squamous cell carcinoma. Some cervical cancers come from HPV infection of gland cells in the cervix and are called adenocarcinomas.


HPV 16+ Cancer Diagnosis and Treatment

The treatment of most HPV infections involves agents that directly ablate the lesions (e.g., surgical excision, chemical ablation, and cryotherapy). Primary prevention of high-risk HPV-induced cancers is now possible via immunization with highly efficacious HPV vaccines.


It covers conventional and current medical therapies and diagnosis available in the HPV 16+ Cancer market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the seven major markets.


The DelveInsight HPV 16+ Cancer market report thoroughly understands HPV 16+ Cancer symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides HPV 16+ Cancer symptoms of treatment algorithms and treatment guidelines for HPV 16+ Cancer symptoms in the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.

HPV 16+ Cancer Epidemiology

The epidemiology division’s HPV 16+ Cancer symptoms provide insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.


Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted HPV 16+ Cancer epidemiology segmented as the incident cases of HPV-induced cancer. The report includes the incident HPV-induced Cancer symptoms in the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.


The total incident cases of HPV-induced Cancer in the 7MM were 99,392 in 2020.

HPV 16+ Cancer Drug Chapters

The drug chapter segment of the HPV 16+ Cancer report encloses the detailed analysis of HPV 16+ Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the HPV 16+ Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.


Currently, there are three commercially available HPV vaccines: Cervarix, a bivalent HPV-16/18 vaccine; Gardasil, a quadrivalent HPV-6/11/16/18 vaccine; and Gardasil9, a nonavalent HPV-6/11/16/18/31/33/45/52/58 vaccine. These components have been included in the forecast model to calculate the approximate revenue estimates during the study period [2018–2030].

Products detail in the report…


HPV 16+ Cancer Emerging Drugs


One major player is PDS Biotech’s lead candidate, PDS0101, which combines the utility of the Versamune platform with targeted antigens in HPV-expressing cancers. In partnership with Merck & Co., PDS Biotech is evaluating a combination of PDS0101 and Keytruda in a phase II study in first-line treatment of recurrent or metastatic head and neck cancer. The current product targets HPV16-positive cancers, and upon successful proof of concept, will be broadened to address cancers caused by other oncogenic HPV types.

HPV 16+ Cancer Market Outlook

The HPV 16+ Cancer market outlook of the report helps build the detailed comprehension of the historic, current, and forecasted HPV 16+ Cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.


This segment gives a thorough detail of HPV 16+ Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight clearly.


According to DelveInsight, the HPV 16+ Cancer market in the 7MM is expected to change in the study period 2018–2030.


Key Findings

This section includes a glimpse of the HPV-induced Cancer market in the 7MM. The market size of HPV-induced Cancer in the 7MM was USD 710 Million in 2020, and the market is estimated to increase during the study period (2018–2030).


The United States Market Outlook

This section provides HPV 16+ Cancer market size and market size by therapies in the United States.


The pipeline scenario is showing early promise with several therapeutic candidates at different stages of clinical development. Many new therapies for HPV 16+ Cancer are in development, many of which have novel targets and mechanisms of action.

 

EU-5 Countries: Market Outlook

The total HPV 16+ Cancer market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided.


Japan: Market Outlook

The total HPV 16+ Cancer market size and market size by therapies in Japan are also mentioned.

HPV 16+ Cancer Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers HPV 16+ Cancer market uptake by drugs, patient uptake by therapies, and drug sales.


This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows comparing the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

HPV 16+ Cancer Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stages. It also analyses HPV 16+ Cancer key players involved in developing targeted therapeutics.


Major players include ISA Pharmaceuticals’s ISA101b and PDS Biotechnology’s PDS0101 being assessed as potential therapies available in the market in the future.

Products detail in the report…


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, merger, licensing, and patent details for HPV 16+ Cancer emerging therapies.

Reimbursement Scenario in HPV 16+ Cancer

While many individuals wait until their claim has been denied before seeking the services of a Social Security attorney, the patient should consider retaining legal representation before submitting the initial application. By working with an attorney or advocate, the patient will ensure that patient’s claim has sufficient supportive medical evidence and that it will be processed through the Compassionate Allowances program. An attorney will do their best to ensure that the patient receives Social Security Disability benefits as quickly as possible and help the patient avoid the lengthy disability appeal process.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinions working in HPV 16+ Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or the HPV 16+ Cancer market trend. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the HPV 16+ Cancer Market using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of HPV 16+ Cancer, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the HPV 16+ Cancer epidemiology and treatment in the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • Additionally, an all-inclusive account of both the current and emerging therapies for HPV 16+ Cancer is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the HPV 16+ Cancer market; historical and forecasted is included in the report, covering drug outreach in the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global HPV 16+ Cancer market

Report Highlights

  • In the coming years, the HPV 16+ Cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world, which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence HPV 16+ Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for HPV 16+ Cancer. The launch of emerging therapies will significantly impact the HPV 16+ Cancer market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for HPV 16+ Cancer.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

HPV 16+ Cancer Report Insights

  • Patient Population
  • Therapeutic Approaches
  • HPV 16+ Cancer Pipeline Analysis
  • HPV 16+ Cancer Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

HPV 16+ Cancer Report Key Strengths

  • 10-year Forecast
  • 7MM Countries Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Market Size by Country
  • Market Size by Therapy

HPV 16+ Cancer Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Emerging Drug Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the HPV 16+ Cancer Market share (%) distribution in 2018, and how would it look like in 2030?
  • What would be the HPV 16+ Cancer total market Size as well as market Size by therapies across the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan during the forecast period (2018–2030)?
  • What are the market’s key findings across the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan and historical as well as forecasted epidemiology during the forecast period (2018–2030)?
  • At what CAGR, the HPV 16+ Cancer market is expected to grow in the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan during the forecast period (2018–2030)?
  • What would be the HPV 16+ Cancer market outlook across the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan during the forecast period (2018–2030)?
  • What would be the HPV 16+ Cancer market growth till 2030, and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of HPV 16+ Cancer?
  • What is the historical HPV 16+ Cancer patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of HPV 16+ Cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about HPV 16+ Cancer?
  • At what CAGR is the population expected to grow during the forecast period (2018–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of HPV 16+ Cancer?
  • What are the current treatment guidelines for treating HPV 16+ Cancer in the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What are HPV 16+ Cancer marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of HPV 16+ Cancer?
  • How many therapies are developed by each company for the treatment of HPV 16+ Cancer?
  • How many emerging therapies are in the mid-stage and late stages of development to treat HPV 16+ Cancer?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the HPV 16+ Cancer therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for HPV 16+ Cancer and its status?
  • What are the key designations that have been granted for the emerging therapies for HPV 16+ Cancer?
  • What are the global historical and forecasted market of HPV 16+ Cancer?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the HPV 16+ Cancer market
  • To understand the future market competition in the HPV 16+ Cancer market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for HPV 16+ Cancer in the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for HPV 16+ Cancer market
  • To understand the future market competition in the HPV 16+ Cancer market

1. Key Insights

2. Report Introduction

3. HPV16+ Cancer Market Overview at a Glance

3.1. Market Share (%) Distribution of HPV16+ Cancer in 2018

3.2. Market Share (%) Distribution of HPV16+ Cancer in 2030

4. Executive Summary of HPV16+ Cancer

5. Disease Background and Overview

5.1. Introduction

5.2. Etiology

5.3. Risk Factors

5.4. Molecular Mechanisms of HPV

5.5. Malignances associated with HPV

5.6. HPV and Cancer Progression

5.7. Diagnosis

5.8. Biomarkers

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Assumption and Rationale

6.3. 7MM Total Incident Patient Population of HPV induced Cancer

6.4. The United States

6.4.1. Incident Cases of HPV induced Cancer in the US

6.5. EU5

6.5.1. Germany

6.5.1.1. Incident Cases of HPV induced Cancer in Germany

6.5.2. France

6.5.2.1. Incident Cases of HPV induced Cancer in France

6.5.3. Italy

6.5.3.1. Incident Cases of HPV induced Cancer in Italy

6.5.4. Spain

6.5.4.1. Incident Cases of HPV16+ Cancer in Spain

6.5.5. United Kingdom

6.5.5.1. Incident Cases of HPV induced Cancer in the UK

6.6. Japan

6.6.1. Incident Cases of HPV induced Cancer in Japan

7. Treatment and Management

7.1. HPV Vaccines

8. Organizations contributing towards HPV16+ Cancer

9. Patient Journey

10. Case Reports

11. Marketed Products

11.1. Gardasil: Merck

11.1.1. Product Description

11.1.2. Mechanism of action

11.1.3. Regulatory Milestones

11.1.4. Side effects of Gardasil

11.1.5. Product Profile

11.2. Gardasil 9: Merck

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Safety and Efficacy of Gardasil 9

11.2.4. Side effects of Gardasil 9

11.2.5. Product Profile

11.3. Cervarix: GlaxoSmithKline

11.3.1. Product Description

11.3.2. Regulatory Milestones

11.3.3. Safety and Efficacy of Cervarix

11.3.4. Side effects of Cervarix

11.3.5. Product Profile

12. Emerging Therapies

12.1. PDS0101: PDS Biotechnology/Merck

12.1.1. Drug Description

12.1.2. Regulatory Milestones

12.1.3. Clinical Development

12.1.3.1. Clinical Trials Information

12.1.4. Product Profile

12.2. CUE-101: Cue Biopharma/Merck

12.2.1. Drug Description

12.2.2. Regulatory Milestones

12.2.3. Clinical Development

12.2.3.1. Clinical Trials Information

12.2.4. Product Profile

12.3. ISA101b: ISA Pharmaceuticals/Regeneron Pharmaceuticals

12.3.1. Drug Description

12.3.2. Regulatory Milestones

12.3.3. Clinical Development

12.3.3.1. Clinical Trials Information

12.3.4. Product Profile

12.4. VB10.16: Vaccibody AS/Roche

12.4.1. Drug Description

12.4.2. Regulatory Milestones

12.4.3. Clinical Development

12.4.3.1. Clinical Trials Information

12.4.4. Product Profile

12.5. TG4001: Transgene

12.5.1. Drug Description

12.5.2. Regulatory Milestones

12.5.3. Clinical Development

12.5.3.1. Clinical Trials Information

12.5.4. Product Profile

12.6. VGX-3100: Innovio Pharma

12.6.1. Drug Description

12.6.2. Regulatory Milestones

12.6.3. Clinical Development

12.6.3.1. Clinical Trials Information

12.6.4. Safety and Efficacy

12.6.5. Product Profile

12.7. HB-201: Hookipa Pharma

12.7.1. Drug Description

12.7.2. Clinical Development

12.7.2.1. Clinical Trials Information

12.7.3. Product Profile

12.8. HB-202: Hookipa Pharma

12.8.1. Drug Description

12.8.2. Clinical Development

12.8.2.1. Clinical Trials Information

12.8.3. Product Profile

12.9. UCPVax: Roche Pharma AG/Invectys

12.9.1. Drug Description

12.9.2. Clinical Development

12.9.2.1. Clinical Trials Information

12.9.3. Product Profile

12.10. BNT113: BioNTech

12.10.1. Drug Description

12.10.2. Regulatory Milestones

12.10.3. Clinical Development

12.10.3.1. Clinical Trials Information

12.10.4. Product Profile

12.11. ADXS 11-001: Advaxis, Inc.

12.11.1. Drug Description

12.11.2. Regulatory Milestones

12.11.3. Clinical Development

12.11.3.1. Clinical Trials Information

12.11.4. Safety and Efficacy

12.11.5. Product Profile

12.12. M7824: Merck

12.12.1. Drug Description

12.12.2. Regulatory Milestones

12.12.3. Clinical Development

12.12.3.1. Clinical Trials Information

12.12.4. Product Profile

12.13. PRGN-2009: Precigen

12.13.1. Drug Description

12.13.2. Clinical Development

12.13.2.1. Clinical Trials Information

12.13.3. Product Profile

13. HPV16+ Cancer: Seven Major Market Analysis

13.1. Key Findings

13.2. Market Size of HPV16+ Cancer in the 7MM

14. Market Outlook

14.1. United States Market Size

14.1.1. Total Market Size of HPV16+ Cancer in the US

14.1.2. Market Size of HPV16+ Cancer by therapies in the US

14.2. EU-5

14.2.1. Germany

14.2.1.1. Total Market size of HPV16+ Cancer in Germany

14.2.1.2. Market Size of HPV16+ Cancer by therapies in Germany

14.2.2. France

14.2.2.1. Total Market size of HPV16+ Cancer in France

14.2.2.2. Market Size of HPV16+ Cancer by therapies in France

14.2.3. Italy

14.2.3.1. Total Market size of HPV16+ Cancer in Italy

14.2.3.2. Market Size of HPV16+ Cancer by therapies in Italy

14.2.4. Spain

14.2.4.1. Total Market size of HPV16+ Cancer in Spain

14.2.4.2. Market Size of HPV16+ Cancer by therapies in Spain

14.2.5. United Kingdom

14.2.5.1. Total Market size of HPV16+ Cancer in the UK

14.2.5.2. Market Size of HPV16+ Cancer by therapies in the UK

14.3. Japan

14.3.1. Total Market size of HPV16+ Cancer in Japan

14.3.2. Market Size of HPV16+ Cancer by Therapies in Japan

15. Market Drivers

16. Market Barriers

17. SWOT Analysis

18. Unmet Needs

19. Market Access and Reimbursement

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Table

Table 1: Summary of HPV16+ Cancer, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Incident Cases of HPV16+ Cancer in the 7MM (2018–2030)

Table 3: Incident Cases of HPV induced Cancer in the US (2018–2030)

Table 4: Incident Cases of HPV induced Cancer in Germany (2018–2030)

Table 5: Incident Cases of HPV induced Cancer in France (2018–2030)

Table 6: Incident Cases of HPV induced Cancer in Italy (2018–2030)

Table 7: Incident Cases of HPV16+ Cancer in Spain (2018–2030)

Table 8: Incident Cases of HPV induced Cancer in the UK (2018–2030)

Table 9: Incident Cases of HPV induced Cancer in Japan (2018–2030)

Table 10: Organizations Contributing Toward the Fight Against HPV16+ Cancer

Table 11: PDS0101, Clinical Trial Description, 2021

Table 12: CUE-101, Clinical Trial Description, 2021

Table 13: VT-1161, Clinical Trial Description, 2021

Table 14: VB10.16, Clinical Trial Description, 2021

Table 15: TG4001, Clinical Trial Description, 2021

Table 16: VGX-3100, Clinical Trial Description, 2021

Table 17: HB-201, Clinical Trial Description, 2021

Table 18: HB-202, Clinical Trial Description, 2021

Table 19: UCPVax, Clinical Trial Description, 2021

Table 20: BNT113, Clinical Trial Description, 2021

Table 21: ADXS11-001, Clinical Trial Description, 2021

Table 22: M7824, Clinical Trial Description, 2021

Table 23: PGRN-2009, Clinical Trial Description, 2021

Table 24: 7 Major Market Size of HPV16+ Cancerin USD Million (2018–2030)

Table 25: The US Market Size of HPV16+ Cancer in USD Million (2018–2030)

Table 26: The US Market Size of HPV16+ Cancer by therapies in USD Million (2018–2030)

Table 27: Germany Market Size of HPV16+ Cancer in USD Million (2018–2030)

Table 28: Germany Market Size of HPV16+ Cancer by therapies in USD Million (2018–2030)

Table 29: France Market Size of HPV16+ Cancer in USD Million (2018–2030)

Table 30: France Market Size of HPV16+ Cancer by therapies in USD Million (2018–2030)

Table 31: Italy Market Size of HPV16+ Cancer in USD Million (2018–2030)

Table 32: Italy Market Size of HPV16+ Cancer by therapies in USD Million (2018–2030)

Table 33: Spain Market Size of HPV16+ Cancer in USD Million (2018–2030)

Table 34: Spain Market Size of HPV16+ Cancer by therapies in USD Million (2018–2030)

Table 35: The UK Market Size of HPV16+ Cancer in USD Million (2018–2030)

Table 36: The UK Market Size of HPV16+ Cancer by therapies in USD Million (2018–2030)

Table 37: Japan Market Size of HPV16+ Cancer in USD Million (2018–2030)

Table 38: Japan Market Size of HPV16+ Cancer by Therapies in USD Million (2018–2030)

List of Figures

Figure 1: Incident cases of HPV induced Cancer in the 7MM (2018–2030)

Figure 2: Incident Cases of HPV induced Cancer in the US (2018–2030)

Figure 3: Incident Cases of HPV induced Cancer in Germany (2018–2030)

Figure 4: Incident Cases of HPV induced Cancer in France (2018–2030)

Figure 5: Incident Cases of HPV induced Cancer in Italy (2018–2030)

Figure 6: Incident Cases of HPV induced Cancer in Spain (2018–2030)

Figure 7: Incident Cases of HPV induced Cancer in the UK (2018–2030)

Figure 8: Incident Cases of HPV induced Cancer in Japan (2018–2030)

Figure 9: 7 Major Market Size of HPV16+ Cancer in USD Million (2018–2030)

Figure 10: The US Market Size of HPV16+ Cancer by Class, USD Million (2018–2030)

Figure 11: The US Market Size of HPV16+ Cancer by therapies in USD Million (2018–2030)

Figure 12: Germany Market Size of HPV16+ Cancer, USD Million (2018–2030)

Figure 13: Germany Market Size of HPV16+ Cancer by therapies in USD Million (2018–2030)

Figure 14: France Market Size of HPV16+ Cancer, USD Million (2018–2030)

Figure 15: France Market Size of HPV16+ Cancer by therapies in USD Million (2018–2030)

Figure 16: Italy Market Size of HPV16+ Cancer, USD Million (2018–2030)

Figure 17: Italy Market Size of HPV16+ Cancer by therapies in USD Million

Figure 18: Spain Market Size of HPV16+ Cancer, USD Million (2018–2030)

Figure 19: Spain Market Size of HPV16+ Cancer by therapies in USD Million (2018–2030)

Figure 20: The UK Market Size of HPV16+ Cancer, USD Million (2018–2030)

Figure 21: The UK Market Size of HPV16+ Cancer by therapies in USD Million (2018–2030)

Figure 22: Japan Market Size of HPV16+ Cancer, USD Million (2018–2030)

Figure 23: Japan Market Size of HPV16+ Cancer by Therapies in USD Million (2018–2030)

Merck

GlaxoSmithKline

PDS Biotechnology/Merck

Cue Biopharma/Merck

ISA Pharmaceuticals/Regeneron Pharmaceuticals

Vaccibody AS/Roche

Transgene

Innovio Pharma

Hookipa Pharma

Roche Pharma AG/Invectys

BioNTech

Advaxis, Inc.

Precigen

Forward to Friend

Need A Quote